CAIDE Looks into the Future: New App from Merz Pharmaceuticals Assesses the Risk of Getting Dementia Within the Next 20 Years

PR57685

FRANKFURT AM MAIN, Germany, Aug. 28 / PRN=KYODO JBN / --

    The CAIDE Dementia Risk App from Merz Pharmaceuticals is available free of

charge for people from 40 to 65 to calculate their individual risk for getting

dementia within the next two decades. Using a traffic light color scheme, the

App can also help physicians discuss preventive measures with patients at risk.

    The new "CAIDE Dementia Risk App (Cardiovascular risk factors, Aging and

Incidence of DEmentia) has been developed in collaboration with Karolinska

Institutet in Stockholm and is available in the App Store for a free download.

The CAIDE App may be used on an iPhone or iPad and comes in two versions: one

for physicians and one for individuals. It is available in five languages:

German, French, Spanish, Russian, and English as default.

    CAIDE supports prevention of dementia

    After entering gender, date of birth, height and weight, cholesterol level,

blood pressure, physical activity and years of education the App calculates the

risk of getting dementia within the next 20 years. If the risk is in the normal

range an orange bar appears. The bar is green if the risk is lower and red if

it is higher than average. Then the physician should discuss preventive

lifestyle interventions.

    Professor Miia Kivipelto who has done the research (1,2) on which the App

is based says: "The biggest risk factor for developing dementia is advanced

age. Large epidemiological studies have demonstrated that what is good for the

heart is good for the brain - in other words, a healthy lifestyle with physical

activity, low blood cholesterol levels, not being obese, and having normal

blood pressure at midlife protects not only against cardiac disease, but also

against dementia."

    More information about Merz on http://www.merz.com.

    1) Kivipelto M et al.; Lancet Neurol 2006;5:735-41

    2) Sindi et al. Poster presented at the 13th Geneva /Springfield Symposium,

March 2014

    Pressekontakt: Merz Pharmaceuticals GmbH

    Dr. Elisabeth Calov

    Tel: +49-(0)69-1503-8428

    E-mail: elisabeth.calov@merz.de

SOURCE: Merz Pharmaceuticals GmbH